{"id":"https://openalex.org/W4403251237","doi":"https://doi.org/10.1016/j.ygyno.2024.07.422","title":"A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update","display_name":"A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update","publication_year":2024,"publication_date":"2024-10-09","ids":{"openalex":"https://openalex.org/W4403251237","doi":"https://doi.org/10.1016/j.ygyno.2024.07.422"},"language":"en","primary_location":{"id":"doi:10.1016/j.ygyno.2024.07.422","doi":"https://doi.org/10.1016/j.ygyno.2024.07.422","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ygyno.2024.07.422","pdf_url":null,"source":{"id":"https://openalex.org/S2574783","display_name":"Gynecologic Oncology","issn_l":"0090-8258","issn":["0090-8258","1095-6859"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gynecologic Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060953135","display_name":"Joyce F. Liu","orcid":"https://orcid.org/0000-0003-3888-3972","observed_orcids":["https://orcid.org/0000-0003-3888-3972"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joyce Liu","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, United States","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021359849","display_name":"David M. O\u2019Malley","orcid":"https://orcid.org/0000-0002-2828-0177","observed_orcids":["https://orcid.org/0000-0002-2828-0177"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David O'Malley","raw_affiliation_strings":["The Ohio State University, Columbus, OH, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, OH, United States","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084817538","display_name":"Els Van Nieuwenhuysen","orcid":"https://orcid.org/0000-0001-5432-1828","observed_orcids":["https://orcid.org/0000-0001-5432-1828"]},"institutions":[{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Els Van Nieuwenhuysen","raw_affiliation_strings":["Leuven Cancer Institute, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leuven Cancer Institute, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053852463","display_name":"Roisin Eilish O'Cearbhaill","orcid":"https://orcid.org/0000-0001-8217-4554","observed_orcids":["https://orcid.org/0000-0001-8217-4554"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roisin O'Cearbhaill","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085452611","display_name":"Sara Bouberhan","orcid":"https://orcid.org/0000-0002-0315-2152","observed_orcids":["https://orcid.org/0000-0002-0315-2152"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Bouberhan","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA, United States","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069337573","display_name":"Kathleen N. Moore","orcid":"https://orcid.org/0000-0002-5803-0718","observed_orcids":["https://orcid.org/0000-0002-5803-0718"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Moore","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, United States","University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, United States","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States","institution_ids":["https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007688933","display_name":"June YiJuan Hou","orcid":"https://orcid.org/0000-0002-6022-0035","observed_orcids":["https://orcid.org/0000-0002-6022-0035"]},"institutions":[{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"June Hou","raw_affiliation_strings":["Columbia University, New York, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University, New York, NY, United States","institution_ids":["https://openalex.org/I78577930"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, United States","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022850951","display_name":"Suk\u2010Young Yoo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suk-Young Yoo","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100372359","display_name":"Bin Wang","orcid":"https://orcid.org/0000-0002-4467-4176","observed_orcids":["https://orcid.org/0000-0002-4467-4176"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bin Wang","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039988535","display_name":"Mary Jane Peterman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Peterman","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043390337","display_name":"Tamara Schmidt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tamara Schmidt","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035392910","display_name":"David A. Knorr","orcid":"https://orcid.org/0000-0002-0766-8914","observed_orcids":["https://orcid.org/0000-0002-0766-8914"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Knorr","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031475492","display_name":"Israel Lowy","orcid":"https://orcid.org/0000-0002-5421-2485","observed_orcids":["https://orcid.org/0000-0002-5421-2485"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Israel Lowy","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050211879","display_name":"Thomas S. Uldrick","orcid":"https://orcid.org/0000-0001-6959-0924","observed_orcids":["https://orcid.org/0000-0001-6959-0924"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Uldrick","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"last","author":{"id":null,"display_name":"Elizabeth Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Miller","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States","institution_ids":["https://openalex.org/I186523950"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4060,"currency":"USD","value_usd":4060},"apc_paid":null,"fwci":0.3946,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.65798445,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"190","issue":null,"first_page":"S284","last_page":"S284"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.5942000150680542,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.5942000150680542,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.2712000012397766,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.08869999647140503,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ca125","display_name":"CA125","score":0.8830000162124634},{"id":"https://openalex.org/keywords/cd3","display_name":"CD3","score":0.671999990940094},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.902999997138977},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.9539999961853027},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9620000123977661},{"id":"https://openalex.org/keywords/t-cell-mediated-cytotoxicity","display_name":"T cell cytotoxicity","score":0.9010000228881836},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6430000066757202},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6050000190734863},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8159999847412109},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9344003200531006},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.6883842945098877},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6053550839424133},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5511094927787781},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5081746578216553},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.43936416506767273},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41433870792388916},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32265666127204895},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.12256208062171936},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.09784367680549622}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.ygyno.2024.07.422","doi":"https://doi.org/10.1016/j.ygyno.2024.07.422","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ygyno.2024.07.422","pdf_url":null,"source":{"id":"https://openalex.org/S2574783","display_name":"Gynecologic Oncology","issn_l":"0090-8258","issn":["0090-8258","1095-6859"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gynecologic Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4400272627","https://openalex.org/W4311139808","https://openalex.org/W4379281531","https://openalex.org/W4388495363","https://openalex.org/W4322011798","https://openalex.org/W7155355414","https://openalex.org/W4387811417","https://openalex.org/W7155398351","https://openalex.org/W4295817096","https://openalex.org/W7129633255"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2024-10-10T00:00:00"}